Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Value Fund median (27 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 28 Nov 2022 – 20 Aug 2026, limited by HSBC Value Fund. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | HSBC Value Fund | Nifty 500 |
|---|---|---|
| 28 Nov 2022 | ₹100.00 | ₹100.00 |
| 21 Mar 2023 | ₹90.17 | ₹91.30 |
| 13 Jul 2023 | ₹103.13 | ₹105.32 |
| 03 Nov 2023 | ₹113.52 | ₹107.71 |
| 25 Feb 2024 | ₹130.84 | ₹128.69 |
| 17 Jun 2024 | ₹150.21 | ₹140.74 |
| 09 Oct 2024 | ₹156.29 | ₹149.51 |
| 30 Jan 2025 | ₹131.46 | ₹134.93 |
| 23 May 2025 | ₹140.62 | ₹144.33 |
| 14 Sep 2025 | ₹144.77 | ₹146.92 |
| 05 Jan 2026 | ₹153.66 | ₹152.42 |
| 29 Apr 2026 | ₹138.87 | ₹144.90 |
| 20 Aug 2026 | ₹142.49 | ₹148.96 |
| Metric | HSBC · Direct · IDCW NAV ₹64.75 Very High risk ★★☆☆☆ | Category median Value Fund · 27 funds |
|---|---|---|
| -3.10% | +2.79% | |
| +9.76% | +12.68% | |
| — | +11.98% | |
| — | +10.69% | |
| +9.97% | +11.75% | |
| +5.92% | — | |
| +12.65% | +13.57% | |
| — | +12.46% | |
| — | +12.08% | |
| Risk | ||
| 17.35% | 14.87% | |
| 0.19 | 0.40 | |
| 0.24 | 0.54 | |
| -25.64% | -37.93% | |
| Nifty 500 | — | |
| -2.48% | +0.85% | |
| 1.11 | 0.95 | |
| 108.5% | 102.9% | |
| 130.6% | 102.9% | |
| 0.90% | 1.20% | |
| ₹14,682Cr | ₹1,405Cr | |
| Up to 1.00% | — | |
| None | — | |
| ₹500 | — | |
| ₹5.00K | — | |
| 30% | 40% | |
| Mayank Chaturvedi | — | |
| 28 Nov 2022 | — | |
| 81 | — | |
| 31.7% | — | |
| 1.7% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.